Instrument Inactif

Autres langues Celsion Corporation Nasdaq

Actions

US15117N4043

Recherche biotechnologique et médicale

Cours en clôture Nasdaq
- ^USD	-

10/09	Imunon, Inc. conclut un accord de recherche et de développement coopératif avec le National Cancer Institute	CI
26/08	IMUNON organise une journée R&D 2026 axée sur l'essai de Phase 3 OVATION 3 et le potentiel clinique d'IMNN-001	CI

Autres langues

10/09	Imunon, Inc. Enters Cooperative Research and Development Agreement with National Cancer Institute
10/09	IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
09/09	IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
26/08	IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001
26/08	IMUNON Hosts 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial And Clinical Potential Of IMNN-001
11/08	Imunon, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
11/08	IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update
04/08	IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026
30/07	IMUNON Reports Strong Enrollment Momentum In Phase 3 OVATION 3 Trial Of IMNN-001 In Advanced Ovarian Cancer
30/07	Imunon Reports Enrollment Above Expectations in Phase 3 Trial of IMNN-001 to Treat Ovarian Cancer
30/07	IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer
23/07	IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development
21/07	Imunon Says Ovarian Cancer Drug Trial Preliminary Results Show Deeper Antitumor Response
21/07	IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
30/06	Imunon, Inc. Appoints Josh Blacher as Principal Financial Officer and Principal Accounting Officer, Effective July 1, 2026
30/06	Imunon, Inc. Announces Chief Financial Officer Changes, Effective July 1, 2026
23/06	IMUNON Inc. Continues Phase 3 OVATION 3 Clinical Trial Of IMNN-001 In Combination With Standard Of Care Chemotherapy
23/06	Imunon's Phase 3 Ovarian Cancer Trial Cleared to Continue
23/06	IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification
22/06	IMUNON to Present at the Life Sciences Investor Forum on June 25th
04/06	IMUNON Announces Up to $10 Million Cash Financing
03/06	Imunon, Inc. announced that it has received $10 million in funding
02/06	Imunon, Inc. announced that it expects to receive $10 million in funding
12/05	IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update
12/05	Imunon, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026